News search

The biomarker MR-proADM improves risk prediction in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and is associated with greater disease severity, mortality, and heart failure events.

Scientist at the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) and the Institute for Research in Biomedicine (IRB Barcelona) uncover a key metabolic mechanism governing immune cell readiness

A prespecified landmark analysis of the REBOOT trial, published in The European Heart Journal Cardiovascular Pharmacotherapy, shows no clinical benefit of beta-blockers during the first year after infarction or beyond one year, in patients without reduced ejection fraction.

A new policy paper highlights key areas for advancing data-driven policymaking to curb the rising burden of non-communicable diseases (NCDs), setting the stage for a more effective and equitable healthcare in Europe 

The Spanish National Center for Cardiovascular Research (CNIC) hosted in Madrid the third General Assembly of JACARDI from October 14 to 16 

Dr. Alegre-Cebollada will be recognized for the pioneering the study of protein mechanics in living systems, revealing how mechanical forces govern protein function and contribute to human disease.